ICCS 2026 puts therapy-aware flow reagents in focus: CD38(VHH) JK36 and TRBC2
Summary
Beckman Coulter's ICCS 2026 poster programme highlights RUO reagent strategies for difficult interpretation contexts: CD38(VHH) clone JK36 for CD38 detection in the presence of anti-CD38 therapy and TRBC1/TRBC2 conjugates for T-cell clonality research. These are not new product launches.
The evidence
The ICCS poster list includes work on anti-CD38(VHH) conjugates after CD38-directed therapies and on TRBC1/TRBC2 conjugates for T-cell clonality assessment. Current catalogue records identify JK36/C94642 as CD38(VHH)-Alexa Fluor 488, 50 tests, liquid, RUO; and SAM.2/D06177 as TCR Cβ2 (TRBC2)-APC, 50 tests, liquid, RUO.
CFCM explainer
Therapy or clonality question → conventional phenotype can become ambiguous → targeted epitope/clonality reagent may improve interpretability.
Source/credit: CFCM conceptual explainer based on primary product pages and ICCS poster titles. Alt text: therapy-aware reagent decision path.
Interpretation and limitations
The event page lists poster titles but not sufficient performance data to assess sensitivity, specificity, interference or clinical utility. Beckman's statement that JK36 recognizes an epitope not masked by daratumumab is a manufacturer product claim; RUO status must remain explicit.
What this means for laboratories
Post-therapy panel design increasingly depends on reagents that remain interpretable after target-directed treatment. JK36 illustrates a therapy-aware reagent strategy: use an analytical epitope intended to remain accessible when conventional anti-CD38 epitopes are occupied. For T-cell clonality, TRBC1/TRBC2 adds another targeted interpretive strategy. CFCM publishes this as WATCH: the reagents and RUO status are verified, while clinical performance and utility require broader independent evidence.
Source Date
Event date
Commercial Regulatory Status
CD38(VHH)-Alexa Fluor 488 clone JK36 and TCR Cβ2 (TRBC2)-APC clone SAM.2 are catalogued as Research Use Only. ICCS poster presence does not change regulatory status.
Primary source
Read the source →An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.
Editor and independence disclosure →CFCM WEEKLY · EVERY SUNDAY
The science behind the signal, in your inbox.
Get evidence-led clinical flow cytometry news, original conference posters, figures from published papers, practical learning pills, an advanced quiz and the story of one CD marker each week. Free. No spam.
Get CFCM Weekly →Complete the form and confirm the email we send you. Unsubscribe any time. Privacy policy.